Corneal Thickness Changes With Scleral Contact Lenses

Changes in Corneal Thickness in Keratoconic Eyes With Variation in Scleral Contact Lens Central Clearance

The purpose of this study is to investigate changes in the corneal thickness of scleral contact lens wearers in a keratoconic (KC) population and compare to age-matched controls. The hypothesis is that scleral contact lens wear is associated with low levels of corneal hypoxia including measurable changes in corneal thickness. Corneal thickness will be altered post scleral lens wear compared to pre-lens wear and the amount of alteration will correlate to the fitting characteristics in the central zone of the scleral lenses. We propose to take a sample of keratoconic and control participants, fit them in scleral lenses, and to measure topographic corneal thickness after 8-10 hours of scleral lens wear after three weeks of wear, to compare two instruments in the measurement of corneal thickness, and to compare the effects of varying central corneal clearance of the scleral lens on corneal thickness.

Study Overview

• Status: Unknown
• Conditions: Keratoconus; Healthy Controls
• Intervention / Treatment: Device: ZenLens™; Device: Zen™ RC

Detailed Description

The purpose of this study is to investigate changes in the corneal thickness of scleral contact lens wearers in a keratoconic (KC) population and compare to age-matched controls. The hypothesis is that scleral contact lens wear is associated with low levels of corneal hypoxia including measurable changes in corneal thickness.

This will be a prospective, dispensing study design. The study will involve up to 20 keratoconic participants and up to 20 age matched controls. Participants will attend 1 screening/fitting visit wearing their habitual contact lenses where the two test lens designs (350 and 450microns) will be fitted. There will then be a delivery visit for each design (randomly selected) and a single follow up visit after 8-10 hours of scleral lens wear, three weeks later. A washout period of a minimum of 48 hours will be applied between the cross-over of each lens design. Lenses to be worn in this study will be made of Boston XO material and are approved by Health Canada. The lenses will have a diameter of 14.8-17.0mm with a high and low sagittal depth in the corneal zone. As to which of the two lenses is being assessed, both the investigator and the participant will be masked as the assistant will provide the lenses in an unlabeled case. Masking the investigator will prevent bias when measuring corneal thickness and analyzing the data. The objectives of this study are to take a sample of keratoconic and control participants, fit them in scleral lenses, and to measure topographic corneal thickness after 8-10 hours of scleral lens wear after three weeks of wear, to compare two instruments in the measurement of corneal thickness, and to compare the effects of varying central corneal clearance of the scleral lens on corneal thickness. Secondary objectives include comparing ocular physiological outcomes between the two test lens designs. Corneal thickness will be altered post scleral lens wear compared to pre-lens wear and the amount of alteration will correlate to the fitting characteristics in the central zone of the scleral lenses.

• Study Type: Interventional
• Enrollment (Anticipated): 40
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Canada
  • Ontario
    • Waterloo, Ontario, Canada, N2L3G1
      • Recruiting
      • University of Waterloo School of Optometry and Vision Science
      • Contact: Kirsten S Carter, BSc OD; Phone Number: 5193018487; Email: kirsten.carter@uwaterloo.ca
      • Contact: Luigina Sorbara, OD MSc; Phone Number: 33085 519-888-4567; Email: gsorbara@uwaterloo.ca

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria (Test Group):

• Had been diagnosed with keratoconus in at least one eye.
• Is at least 18 years of age and has full legal capacity to volunteer.
• Has read and understood the information consent letter.
• Is willing and able to follow instructions and maintain the appointment schedule.

Inclusion Criteria (Control Group)

• Had been NOT diagnosed with keratoconus in at least one eye.
• Is at least 18 years of age and has full legal capacity to volunteer.
• Has read and understood the information consent letter.
• Is willing and able to follow instructions and maintain the appointment schedule.

Exclusion Criteria (Test Group):

• Is using any topical medications that will affect ocular health.
• Has any ocular pathology or severe insufficiency of lacrimal secretion (severe dry eyes) that would affect the wearing of contact lenses.
• Has persistent, clinically significant corneal or conjunctival staining using sodium fluorescein dye.
• Has any clinically significant lid or conjunctival abnormalities and active neovascularization.
• Is aphakic.
• Has undergone penetrating keratoplasty.
• Is participating in any other type of eye related clinical or research study.
• Has any known allergies or sensitivity to the diagnostic pharmaceuticals or products, such as fluorescein, used in this study.

Exclusion Criteria (Control Group):

• Is using any topical medications that will affect ocular health.
• Has any ocular pathology or severe insufficiency of lacrimal secretion (severe dry eyes) that would affect the wearing of contact lenses.
• Has persistent, clinically significant corneal or conjunctival staining using sodium fluorescein dye.
• Has any clinically significant lid or conjunctival abnormalities and active neovascularization.
• Is aphakic.
• Has undergone any corneal surgery.
• Is participating in any other type of eye related clinical or research study.
• Has any known allergies or sensitivity to the diagnostic pharmaceuticals or products, such as fluorescein, used in this study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Keratoconics wearing ZenLens with high central clearance; Scleral contact lenses designed to provide approximately 450 microns of central clearance.	Device: ZenLens™; The ZenLens™ semi-scleral lenses are manufactured by Alden Optic Laboratories Inc., Lancaster, NY. They will be made in Boston XO material.
Experimental: Keratoconics wearing ZenLens with low central clearance; Scleral contact lenses designed to provide approximately 350 microns of central clearance.	Device: ZenLens™; The ZenLens™ semi-scleral lenses are manufactured by Alden Optic Laboratories Inc., Lancaster, NY. They will be made in Boston XO material.
Active Comparator: Healthy controls wearing ZenLens with high central clearance; Scleral contact lenses designed to provide approximately 450 microns of central clearance.	Device: Zen™ RC; The Zen™ RC semi-scleral lenses are manufactured by Alden Optic Laboratories Inc., Lancaster, NY. They will be made in Boston XO material.
Active Comparator: Healthy controls wearing ZenLens with low central clearance; Scleral contact lenses designed to provide approximately 350 microns of central clearance.	Device: Zen™ RC; The Zen™ RC semi-scleral lenses are manufactured by Alden Optic Laboratories Inc., Lancaster, NY. They will be made in Boston XO material.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Corneal Thickness	Corneal thickness after 8-10 hours of scleral contact lens wear will be measured with the Spectralis OCT and Oculus Pentacam	6 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Visual acuity	Both high and low contrast visual acuity will be measured before and after 8-10 hours of scleral contact lens wear	6 weeks
Conjunctival redness	Conjunctival redness will be measured with the Keratograph before and after 8-10 hours of scleral lens wear	6 weeks
Corneal and conjunctival staining	Corneal and conjunctival staining will be assessed with the Keratograph and biomicroscope before and after 8-10 hours of scleral lens wear	6 weeks
Tear biochemistry: proteases and cytokines	The level of proteases (MMP-1, MMP-9) and cytokines (IL-1, IL-6, IL-8, TNFα) in each of the tear samples collected from the lenses will be measured using the Meso Scale Discovery System (MSD-ECL) before and after 8-10 hours of scleral lens wear.	6 weeks
Tear biochemistry: cell count	Polymorphonuclear leukocyte (PMN) cells in each of the tear samples collected from the lenses will be analyzed and counted using the BD FACS Calibur™ Flow Cytometer and Bright-Line Hemacytometer before and after 8-10 hours of scleral lens wear.	6 weeks

Collaborators and Investigators

• Sponsor: University of Waterloo
• Collaborators: Bausch & Lomb Incorporated
• Investigators: Principal Investigator: Luigina Sorbara, OD MSc, University of Waterloo

Publications and helpful links

General Publications

• van der Worp E, Bornman D, Ferreira DL, Faria-Ribeiro M, Garcia-Porta N, Gonzalez-Meijome JM. Modern scleral contact lenses: A review. Cont Lens Anterior Eye. 2014 Aug;37(4):240-50. doi: 10.1016/j.clae.2014.02.002. Epub 2014 Mar 12.
• Romero-Rangel T, Stavrou P, Cotter J, Rosenthal P, Baltatzis S, Foster CS. Gas-permeable scleral contact lens therapy in ocular surface disease. Am J Ophthalmol. 2000 Jul;130(1):25-32. doi: 10.1016/s0002-9394(00)00378-0.
• Walker MK, Bergmanson JP, Miller WL, Marsack JD, Johnson LA. Complications and fitting challenges associated with scleral contact lenses: A review. Cont Lens Anterior Eye. 2016 Apr;39(2):88-96. doi: 10.1016/j.clae.2015.08.003. Epub 2015 Sep 2.
• Ucakhan OO, Ozkan M, Kanpolat A. Corneal thickness measurements in normal and keratoconic eyes: Pentacam comprehensive eye scanner versus noncontact specular microscopy and ultrasound pachymetry. J Cataract Refract Surg. 2006 Jun;32(6):970-7. doi: 10.1016/j.jcrs.2006.02.037.
• Liesegang TJ. Contact lens-related microbial keratitis: Part I: Epidemiology. Cornea. 1997 Mar;16(2):125-31.

Study record dates

Study Major Dates

• Study Start (Actual): June 22, 2017
• Primary Completion (Anticipated): December 1, 2020
• Study Completion (Anticipated): December 1, 2020

Study Registration Dates

• First Submitted: June 15, 2017
• First Submitted That Met QC Criteria: August 14, 2017
• First Posted (Actual): August 15, 2017

Study Record Updates

• Last Update Posted (Actual): April 10, 2020
• Last Update Submitted That Met QC Criteria: April 8, 2020
• Last Verified: April 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Eye Diseases; Corneal Diseases; Keratoconus
• Other Study ID Numbers: 22186

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No